Welcome to our dedicated page for Spectral AI news (Ticker: MDAI), a resource for investors and traders seeking the latest updates and insights on Spectral AI stock.
Spectral AI, Inc. develops artificial intelligence medical diagnostics for wound care, with the DeepView System as its principal platform for burn-wound assessment. DeepView combines multispectral imaging with a proprietary AI algorithm to evaluate the healing potential of burn wounds and provide a binary prediction on whether tissue is likely to heal within a specified period.
Recurring news about Spectral AI covers DeepView presentations at burn-care medical meetings, BARDA funding for burn imaging technology, FDA De Novo 510(k) activity, financial results, commercialization preparation, stockholder meetings and executive appointments. Company updates also describe research and development revenue tied to government-supported development work and governance matters associated with its Nasdaq-listed common stock.
Spectral AI (Nasdaq: MDAI) will release its 2026 second quarter financial results for the period ended June 30, 2026 on Tuesday, August 11, 2026, after the close of the Nasdaq market. A conference call to discuss the results is scheduled for 5:00 p.m. Eastern Time the same day, with U.S. and international dial-in numbers and a simultaneous webcast available via the Events section of the company’s investor relations website.
Spectral AI (Nasdaq:MDAI) appointed industry veteran Darcy Bajko as Chief Commercial Officer, effective July 31, 2026. She will lead global commercialization of the FDA De Novo–cleared DeepView® System for burn indication as the company pivots from product development to commercial execution.
DeepView is a non-invasive, AI-driven imaging device that rapidly predicts burn wound healing potential to guide treatment decisions.
Spectral AI (Nasdaq:MDAI)/b) highlighted its DeepView® System at the 2026 British Burn Association conference in Nottingham, featuring multiple podium and poster presentations. Dr. Jeffrey Carter’s paper on multispectral imaging with AI for burn wounds received BBA’s 1st Prize oral presentation award.The company noted prior FDA De Novo Classification for DeepView in May 2026 and initial UKCA authorization in February 2024. DeepView is a non-invasive, AI-driven device providing rapid, data-based assessments of burn wound healing potential, trained on over 340 billion pixels of image data.
Spectral AI (Nasdaq:MDAI) is partnering with the American Board of Wound Management Foundation to celebrate the 10th Annual Wound Healing Awareness Month during June 2026.
The company highlights its DeepView System for burn indication, which received FDA De Novo Classification in May 2026, and supports faster, data-driven wound care decisions.
Spectral AI (Nasdaq:MDAI) will participate in the 2026 British Burn Association Annual Meeting, June 17-19, 2026, in Nottingham, England. The FDA-cleared DeepView System for burn indication will be displayed at Stand #22 and featured in multiple podium and poster presentations.
The system has FDA De Novo Classification (May 2026) and initial UKCA authorization (February 2024). Spectral AI expects first commercial DeepView sales by year-end 2026.
Spectral AI (Nasdaq:MDAI) reported voting results from its May 29, 2026 Annual Meeting, where all proposals, including director elections, auditor ratification and share reservation under an October 24, 2025 Securities Purchase Agreement, were approved.
The company highlighted FDA De Novo clearance for its DeepView System for burn indication, $31.7 million in BARDA funding, delivery of a handheld prototype under a Department of Defense contract, and plans to generate initial DeepView commercial sales in the US and internationally by late 2026.
Spectral AI (Nasdaq: MDAI) received FDA De Novo Classification for its DeepView® System for burn indication, authorizing commercial distribution in the United States. The non-invasive device uses multispectral imaging and AI to assess burn wounds’ 21-day healing potential, supporting faster, data-driven treatment decisions in burn, trauma, and emergency settings.
Spectral AI (Nasdaq:MDAI) reported Q1 2026 results and updated its 2026 outlook. R&D revenue was $4.0 million versus $6.7 million, while gross margin improved to 50.8% from 47.2%. The company recorded a net loss of $3.4 million versus prior-year net income of $2.9 million, mainly from warrant liability revaluation.
Cash was $11.7 million on March 31, 2026. Spectral AI highlighted $31.7 million in advanced, non-dilutive BARDA funding supporting DeepView development, reiterated full-year 2026 revenue guidance of about $18.5 million, and announced David McGuire as Chief Financial Officer.
Spectral AI (Nasdaq: MDAI) received the Small Business Innovator Award at the inaugural Texas Innovation Conference on April 22-23, 2026.
The company was recognized for its DeepView® System, an AI-driven multispectral imaging platform to assess burn-wound healing potential. Spectral AI submitted a De Novo clearance application to the FDA in June 2025. Representatives Jason Dwight and Bob Spencer accepted the award.
Spectral AI (Nasdaq: MDAI) will report Q1 2026 financial results for the quarter ended March 31, 2026 on Tuesday, May 12, 2026 after Nasdaq market close, with a conference call at 5:00 PM ET and a simultaneous webcast available on the company investor relations Events page.